Fig. 2.

Univariate sensitivity analyses for parameter impact on incremental costs per QALY gained. Notes: The top 10 most impactful parameters included in univariate sensitivity analyses are shown above. For the list of parameters included in the analyses and the associated deterministic point estimates, standard errors, and distributions, please refer to Supplementary Table 6 in the electronic supplementary material. In these sensitivity analyses, negative costs per QALY gained indicate that the vericiguat plus PSoCT arm is dominated by PSoCT alone. CV cardiovascular, exp. Exponential, Gen. gamma generalized gamma, HFH heart failure hospitalization, NT-proBNP N-terminal pro-B-type natriuretic peptide, PSoCT prior standard-of-care therapies, QALY quality-adjusted life-year